Viewing Study NCT07185256

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:24 PM
Ignite Modification Date: 2026-06-18 @ 8:25 PM
Study NCT ID: NCT07185256
Status: RECRUITING
Last Update Posted: 2025-12-17
First Post: 2025-07-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
Sponsor: Opus Genetics, Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None ARB View
None BVMD View
None Autosomal-Dominant Bestrophinopathy View
None Best Vitelliform Macular Dystrophy View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Bestrophinopathy View
None BVMD View
None ARB View
None OPGx-BEST1 View
None Best vitelliform macular dystrophy View
None Autosomal-Dominant Bestrophinopathy View